BACKGROUND. To define better the efficacy of vasodilator therapy in the treatment of chronic congestive heart failure, we compared the effects of hydralazine and isosorbide dinitrate with those of enalapril in 804 men receiving digoxin and diuretic therapy for heart failure. The patients were randomly assigned in a double-blind manner to receive 20 mg of enalapril daily or 300 mg of hydralazine plus 160 mg of isosorbide dinitrate daily. The latter regimen was identical to that used with a similar patient population in the effective-treatment arm of our previous Vasodilator-Heart Failure Trial. RESULTS. Mortality after two years was significantly lower in the enalapril arm (18 percent) than in the hydralazine-isosorbide dinitrate arm (25 percent) (P = 0.016; reduction in mortality, 28.0 percent), and overall mortality tended to be lower (P = 0.08). The lower mortality in the enalapril arm was attributable to a reduction in the incidence of sudden death, and this beneficial effect was more prominent in patients with less severe symptoms (New York Heart Association class I or II). In contrast, body oxygen consumption at peak exercise was increased only by hydralazine-isosorbide dinitrate treatment (P less than 0.05), and left ventricular ejection fraction, which increased with both regimens during the 2 years after randomization, increased more (P less than 0.05) during the first 13 weeks in the hydralazine-isosorbide dinitrate group. CONCLUSIONS. The similar two-year mortality in the hydralazine-isosorbide dinitrate arms in our previous Vasodilator-Heart Failure Trial (26 percent) and in the present trial (25 percent), as compared with that in the placebo arm in the previous trial, (34 percent) and the further survival benefit with enalapril in the present trial (18 percent) strengthen the conclusion that vasodilator therapy should be included in the standard treatment for heart failure. The different effects of the two regimens (enalapril and hydralazine-isosorbide dinitrate) on mortality and physiologic end points suggest that the profile of effects might be enhanced if the regimens were used in combination.
Source Information
University of Minnesota Medical School, Minneapolis 55455.
This article has been cited by other articles:
Authors/Task Force Members, , Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J. J.V., Ponikowski, P., Poole-Wilson, P. A., Stromberg, A., van Veldhuisen, D. J., Atar, D., Hoes, A. W., Keren, A., Mebazaa, A., Nieminen, M., Priori, S. G., Swedberg, K., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., Document Reviewers, , Tendera, M., Auricchio, A., Bax, J., Bohm, M., Corra, U., della Bella, P., Elliott, P. M., Follath, F., Gheorghiade, M., Hasin, Y., Hernborg, A., Jaarsma, T., Komajda, M., Kornowski, R., Piepoli, M., Prendergast, B., Tavazzi, L., Vachiery, J.-L., Verheugt, F. W. A., Zamorano, J. L., Zannad, F.
(2008). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J
29: 2388-2442
[Full Text]
Ellison, G. T. H., Kaufman, J. S., Head, R. F., Martin, P. A., Kahn, J. D.
(2008). Flaws in the U.S. Food and Drug Administration's Rationale for Supporting the Development and Approval of BiDil as a Treatment for Heart Failure Only in Black Patients.. J Law Med Ethics
36: 449-457
Crespo, M. J., Cruz, N., Altieri, P. I., Escobales, N.
(2008). Enalapril and Losartan Are More Effective Than Carvedilol in Preventing Dilated Cardiomyopathy in the Syrian Cardiomyopathic Hamster. J CARDIOVASC PHARMACOL THER
13: 199-206
[Abstract]
Mullens, W., Abrahams, Z., Francis, G. S., Skouri, H. N., Starling, R. C., Young, J. B., Taylor, D. O., Tang, W.H. W.
(2008). Sodium nitroprusside for advanced low-output heart failure.. J Am Coll Cardiol
52: 200-207
[Abstract][Full Text]
Becker, R. C., Meade, T. W., Berger, P. B., Ezekowitz, M., O'Connor, C. M., Vorchheimer, D. A., Guyatt, G. H., Mark, D. B., Harrington, R. A.
(2008). The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest
133: 776S-814S
[Abstract][Full Text]
Cotrufo, M., De Santo, L. S., Corte, A. D., Romano, G., Amarelli, C., De Feo, M., Santarpino, G., Scardone, M., Nappi, G.
(2008). Acute hemodynamic and functional effects of surgical ventricular restoration and heart transplantation in patients with ischemic dilated cardiomyopathy.. J. Thorac. Cardiovasc. Surg.
135: 1054-1060
[Abstract][Full Text]
Squire, I.
(2008). Assessing prognosis in heart failure: you can see a lot if you look, but more if you look again ... ... .... Eur Heart J
29: 959-960
[Full Text]
Sharma, V., Dhillon, P., Wambolt, R., Parsons, H., Brownsey, R., Allard, M. F., McNeill, J. H.
(2008). Metoprolol improves cardiac function and modulates cardiac metabolism in the streptozotocin-diabetic rat. Am. J. Physiol. Heart Circ. Physiol.
294: H1609-H1620
[Abstract][Full Text]
Saha, S. A., Molnar, J., Arora, R. R.
(2007). Tissue ACE Inhibitors for Secondary Prevention of Cardiovascular Disease in Patients With Preserved Left Ventricular Function: A Pooled Meta-analysis of Randomized Placebo-controlled Trials. J CARDIOVASC PHARMACOL THER
12: 192-204
[Abstract]
Borer, J. S.
(2007). Angiotensin-converting enzyme inhibition: a landmark advance in treatment for cardiovascular diseases. Eur Heart J Suppl
9: E2-E9
[Abstract][Full Text]
Kreimer, S.
(2007). BiDil Not Widely Prescribed. DOC News
4: 23-23
[Full Text]
Fruhwald, F. M., Fahrleitner-Pammer, A., Berger, R., Leyva, F., Freemantle, N., Erdmann, E., Gras, D., Kappenberger, L., Tavazzi, L., Daubert, J.-C., Cleland, J. G.F.
(2007). Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J
28: 1592-1597
[Abstract][Full Text]
Patel, J., Heywood, J. T.
(2007). Mode of Death in Patients With Systolic Heart Failure. J CARDIOVASC PHARMACOL THER
12: 127-136
[Abstract]
Allen, L. A., O'Connor, C. M.
(2007). Management of acute decompensated heart failure. CMAJ
176: 797-805
[Abstract][Full Text]
Bibbins-Domingo, K., Fernandez, A.
(2007). BiDil for Heart Failure in Black Patients: Implications of the U.S. Food and Drug Administration Approval. ANN INTERN MED
146: 52-56
[Abstract][Full Text]
Temple, R., Stockbridge, N. L.
(2007). BiDil for Heart Failure in Black Patients: The U.S. Food and Drug Administration Perspective. ANN INTERN MED
146: 57-62
[Abstract][Full Text]
Taylor, A. L., Lindenfeld, J., Ziesche, S., Walsh, M. N., Mitchell, J. E., Adams, K., Tam, S. W., Ofili, E., Sabolinski, M. L., Worcel, M., Cohn, J. N., for the A-HeFT Investigators,
(2006). Outcomes by Gender in the African-American Heart Failure Trial. J Am Coll Cardiol
48: 2263-2267
[Abstract][Full Text]
Brody, H., Hunt, L. M.
(2006). BiDil: Assessing a Race-Based Pharmaceutical. Ann Fam Med
4: 556-560
[Abstract][Full Text]
Edwards, N.C., Steeds, R.P., Ferro, C.J., Townend, J.N.
(2006). The treatment of coronary artery disease in patients with chronic kidney disease. QJM
99: 723-736
[Abstract][Full Text]
Pfeffer, M. A., Frohlich, E. D.
(2006). Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation. Am. J. Physiol. Heart Circ. Physiol.
291: H2021-H2025
[Abstract][Full Text]
Sarkar, P., Nicholson, G., Hall, G.
(2006). Brief review: Angiotensin converting enzyme inhibitors and angioedema: anesthetic implications: [Revue sommaire sur les implications anesthesiques de l'oedeme de Quincke et des inhibiteurs de l'enzyme de conversion de l'angiotensine].. Canadian J. Anesthesia
53: 994-1003
[Abstract][Full Text]
Gheorghiade, M., Sopko, G., De Luca, L., Velazquez, E. J., Parker, J. D., Binkley, P. F., Sadowski, Z., Golba, K. S., Prior, D. L., Rouleau, J. L., Bonow, R. O.
(2006). Navigating the Crossroads of Coronary Artery Disease and Heart Failure. Circulation
114: 1202-1213
[Full Text]
Dolezal, T.
(2006). Review: Imidapril in Heart Failure. Journal of Renin-Angiotensin-Aldosterone System
7: 146-154
[Abstract]
Groban, L., Butterworth, J.
(2006). Perioperative management of chronic heart failure.. Anesth. Analg.
103: 557-575
[Abstract][Full Text]
Howard, P. A, Cheng, J. W., Crouch, M. A, Colucci, V. J, Kalus, J. S, Spinler, S. A, Munger, M.
(2006). Drug Therapy Recommendations from the 2005 ACC/AHA Guidelines for Treatment of Chronic Heart Failure. The Annals of Pharmacotherapy
40: 1607-1616
[Abstract][Full Text]
Haga, S. B., Ginsburg, G. S.
(2006). Prescribing BiDil: Is It Black and White?. J Am Coll Cardiol
48: 12-14
[Abstract][Full Text]
Lechat, P.
(2006). The evolution of heart failure management over recent decades: from CONSENSUS to CIBIS. Eur Heart J Suppl
8: C5-C12
[Abstract][Full Text]
Funck-Brentano, C.
(2006). Beta-blockade in CHF: from contraindication to indication. Eur Heart J Suppl
8: C19-C27
[Abstract][Full Text]
Enseleit, F., Duru, F.
(2006). Long-term continuous external electrocardiographic recording: a review.. Europace
8: 255-266
[Abstract][Full Text]
Carson, P., Anand, I., O'Connor, C., Jaski, B., Steinberg, J., Lwin, A., Lindenfeld, J., Ghali, J., Barnet, J. H., Feldman, A. M., Bristow, M. R.
(2005). Mode of Death in Advanced Heart Failure: The Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) Trial. J Am Coll Cardiol
46: 2329-2334
[Abstract][Full Text]
Barr, D. A.
(2005). The Practitioner's Dilemma: Can We Use a Patient's Race To Predict Genetics, Ancestry, and the Expected Outcomes of Treatment?. ANN INTERN MED
143: 809-815
[Abstract][Full Text]
Aronow, W. S.
(2005). Drug Treatment of Systolic and of Diastolic Heart Failure in Elderly Persons. J. Gerontol. A Biol. Sci. Med. Sci.
60: 1597-1605
[Abstract][Full Text]
The ESCAPE Investigators and ESCAPE Study Coordina,
(2005). Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness: The ESCAPE Trial. JAMA
294: 1625-1633
[Abstract][Full Text]
Reiffel, J. A.
(2005). Drug and Drug-Device Therapy in Heart Failure Patients in the Post-COMET and SCD-HeFT Era. J CARDIOVASC PHARMACOL THER
10: S45-S58
[Abstract]
Developed in Collaboration With the American Colle, , Endorsed by the Heart Rhythm Society, , Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., Oates, J. A., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W., Antman, E. M., Smith, S. C. Jr, Adams, C. D., Anderson, J. L., Faxon, D. P., Fuster, V., Halperin, J. L., Hiratzka, L. F., Hunt, S. A., Jacobs, A. K., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B.
(2005). ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol
46: 1116-1143
[Full Text]
Doehner, W., Rauchhaus, M., Ponikowski, P., Godsland, I. F., von Haehling, S., Okonko, D. O., Leyva, F., Proudler, A. J., Coats, A. J.S., Anker, S. D.
(2005). Impaired Insulin Sensitivity as an Independent Risk Factor for Mortality in Patients With Stable Chronic Heart Failure. J Am Coll Cardiol
46: 1019-1026
[Abstract][Full Text]
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., Oates, J. A., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W., Antman, E. M., Smith, S. C. Jr, Adams, C. D., Anderson, J. L., Faxon, D. P., Fuster, V., Halperin, J. L., Hiratzka, L. F., Hunt, S. A., Jacobs, A. K., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B.
(2005). ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation
112: 1825-1852
[Full Text]
Mancini, D., Burkhoff, D.
(2005). Mechanical Device-Based Methods of Managing and Treating Heart Failure. Circulation
112: 438-448
[Abstract][Full Text]
Ioannidis, J. P. A.
(2005). Contradicted and Initially Stronger Effects in Highly Cited Clinical Research. JAMA
294: 218-228
[Abstract][Full Text]
Heywood, J. T., Elatre, W., Pai, R. G., Fabbri, S., Huiskes, B.
(2005). Simple Clinical Criteria to Determine the Prognosis of Heart Failure. J CARDIOVASC PHARMACOL THER
10: 173-180
[Abstract]
Authors/Task Force Members, , Swedberg, K., Writing Committee:, , Cleland, J., Dargie, H., Drexler, H., Follath, F., Komajda, M., Tavazzi, L., Smiseth, O. A., Other Contributors, , Gavazzi, A., Haverich, A., Hoes, A., Jaarsma, T., Korewicki, J., Levy, S., Linde, C., Lopez-Sendon, J.-L., Nieminen, M. S., Pierard, L., Remme, W. J.
(2005). Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J
26: 1115-1140
[Full Text]
Burkhoff, D., Ben-Haim, S. A.
(2005). Nonexcitatory electrical signals for enhancing ventricular contractility: rationale and initial investigations of an experimental treatment for heart failure. Am. J. Physiol. Heart Circ. Physiol.
288: H2550-H2556
[Full Text]
Mann, D. L., Bristow, M. R.
(2005). Mechanisms and Models in Heart Failure: The Biomechanical Model and Beyond. Circulation
111: 2837-2849
[Full Text]
Patwala, A Y, Wright, D J
(2005). Device based treatment of heart failure. Postgrad. Med. J.
81: 286-291
[Abstract][Full Text]
Epstein, B. J, Gums, J. G
(2005). Angiotensin Receptor Blockers versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations. The Annals of Pharmacotherapy
39: 470-480
[Abstract][Full Text]
Yan, A. T., Yan, R. T., Liu, P. P.
(2005). Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials. ANN INTERN MED
142: 132-145
[Abstract][Full Text]
Bloche, M. G.
(2004). Race-Based Therapeutics. NEJM
351: 2035-2037
[Full Text]
Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R. Jr., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., Cohn, J. N., the African-American Heart Failure Trial Investiga,
(2004). Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure. NEJM
351: 2049-2057
[Abstract][Full Text]
The PEACE Trial Investigators,
(2004). Angiotensin-Converting-Enzyme Inhibition in Stable Coronary Artery Disease. NEJM
351: 2058-2068
[Abstract][Full Text]
Hare, J. M.
(2004). Nitroso-Redox Balance in the Cardiovascular System. NEJM
351: 2112-2114
[Full Text]
Leier, C. V.
(2004). Dismantling mandates in the treatment of heart failure. J Am Coll Cardiol
44: 1831-1833
[Full Text]
Aronow, W. S.
(2004). Management of the Elderly Person After Myocardial Infarction. J. Gerontol. A Biol. Sci. Med. Sci.
59: 1173-1185
[Abstract][Full Text]
Karim, S. M., Rhee, A. Y., Given, A. M., Faulx, M. D., Hoit, B. D., Brozovich, F. V.
(2004). Vascular Reactivity in Heart Failure: Role of Myosin Light Chain Phosphatase. Circ. Res.
95: 612-618
[Abstract][Full Text]
Teo, K. K., Mitchell, L. B., Pogue, J., Bosch, J., Dagenais, G., Yusuf, S., on behalf of the HOPE Investigators,
(2004). Effect of Ramipril in Reducing Sudden Deaths and Nonfatal Cardiac Arrests in High-Risk Individuals Without Heart Failure or Left Ventricular Dysfunction. Circulation
110: 1413-1417
[Abstract][Full Text]
Felker, G.M., Adams, K. F. Jr, Gattis, W. A., O'Connor, C. M.
(2004). Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol
44: 959-966
[Abstract][Full Text]
Harrington, R. A., Becker, R. C., Ezekowitz, M., Meade, T. W., O'Connor, C. M., Vorchheimer, D. A., Guyatt, G. H.
(2004). Antithrombotic Therapy for Coronary Artery Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest
126: 513S-548S
[Abstract][Full Text]
Task Force Members, , Lopez-Sendon, J., Swedberg, K., McMurray, J., Tamargo, J., Maggioni, A. P., Dargie, H., Tendera, M., Waagstein, F., Kjekshus, J., Lechat, P., Pedersen, C. T.
(2004). Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease: The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J
25: 1454-1470
[Full Text]
Sondhi, D., Lippmann, M., Murali, G.
(2004). Airway Compromise Due to Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema: Clinical Experience at a Large Community Teaching Hospital. Chest
126: 400-404
[Abstract][Full Text]
Milani, R. V., Lavie, C. J., Mehra, M. R.
(2004). Cardiopulmonary Exercise Testing: How Do We Differentiate the Cause of Dyspnea?. Circulation
110: e27-e31
[Full Text]
Gluckman, T. J., Baranowski, B., Ashen, M. D., Henrikson, C. A., McAllister, M., Braunstein, J. B., Blumenthal, R. S.
(2004). A Practical and Evidence-Based Approach to Cardiovascular Disease Risk Reduction. Arch Intern Med
164: 1490-1500
[Abstract][Full Text]
Ingwall, J. S., Weiss, R. G.
(2004). Is the Failing Heart Energy Starved?: On Using Chemical Energy to Support Cardiac Function. Circ. Res.
95: 135-145
[Abstract][Full Text]
Rahimtoola, S. H.
(2004). Digitalis Therapy for Patients in Clinical Heart Failure. Circulation
109: 2942-2946
[Full Text]
Hall, J. L., Grindle, S., Han, X., Fermin, D., Park, S., Chen, Y., Bache, R. J., Mariash, A., Guan, Z., Ormaza, S., Thompson, J., Graziano, J., de Sam Lazaro, S. E., Pan, S., Simari, R. D., Miller, L. W.
(2004). Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks. Physiol. Genomics
17: 283-291
[Abstract][Full Text]
Roffman, D. S
(2004). High-Versus Low-Dose ACE Inhibitor Therapy in Chronic Heart Failure. The Annals of Pharmacotherapy
38: 831-838
[Abstract][Full Text]
Fletcher, J., Buch, A. N., Routledge, H. C., Chowdhary, S., Coote, J. H., Townend, J. N.
(2004). Acute aldosterone antagonism improves cardiac vagal control in humans. J Am Coll Cardiol
43: 1270-1275
[Abstract][Full Text]
Cook, J., Drummond, M., Heyse, J. F
(2004). Economic endpoints in clinical trials. Stat Methods Med Res
13: 157-176
[Abstract]
Mansfield, D. R., Gollogly, N. C., Kaye, D. M., Richardson, M., Bergin, P., Naughton, M. T.
(2004). Controlled Trial of Continuous Positive Airway Pressure in Obstructive Sleep Apnea and Heart Failure. Am. J. Respir. Crit. Care Med.
169: 361-366
[Abstract][Full Text]
Laverman, G. D., Remuzzi, G., Ruggenenti, P.
(2004). ACE Inhibition versus Angiotensin Receptor Blockade: Which Is Better for Renal and Cardiovascular Protection?. J. Am. Soc. Nephrol.
15: S64-70
[Abstract][Full Text]
Pina, I. L.
(2003). A better survival for women with heart failure? it's not so simple.... J Am Coll Cardiol
42: 2135-2138
[Full Text]
Feldman, A. M.
(2003). The emerging role of pharmacogenomics in the treatment of patients with heart failure. Ann. Thorac. Surg.
76: S2246-2253
[Full Text]
Shah, P. J., Hare, D. L., Raman, J. S., Gordon, I., Chan, R. K., Horowitz, J. D., Rosalion, A., Buxton, B. F.
(2003). Survival after myocardial revascularization for ischemic cardiomyopathy: A prospective ten-year follow-up study. J. Thorac. Cardiovasc. Surg.
126: 1320-1327
[Abstract][Full Text]
Warner Stevenson, L.
(2003). The points for pacing. J Am Coll Cardiol
42: 1460-1462
[Full Text]
Domanski, M., Krause-Steinrauf, H., Deedwania, P., Follmann, D., Ghali, J. K., Gilbert, E., Haffner, S., Katz, R., Lindenfeld, J., Lowes, B. D., Martin, W., McGrew, F., Bristow, M. R., BEST Investigators,
(2003). The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol
42: 914-922
[Abstract][Full Text]
Bell, D. S.H.
(2003). Heart Failure: The frequent, forgotten, and often fatal complication of diabetes. Diabetes Care
26: 2433-2441
[Abstract][Full Text]
Horlander, K. T., Mannino, D. M., Leeper, K. V.
(2003). Pulmonary Embolism Mortality in the United States, 1979-1998: An Analysis Using Multiple-Cause Mortality Data. Arch Intern Med
163: 1711-1717
[Abstract][Full Text]
Cheng, R. M., Mamdani, M., Jackevicius, C. A, Tu, K.
(2003). Association Between ACE Inhibitors and Acute Pancreatitis in the Elderly. The Annals of Pharmacotherapy
37: 994-998
[Abstract][Full Text]
Remme, W.J.
(2003). Reconsider the management of all coronary artery disease patients: Importance of the EUROPA trial. Eur Heart J Suppl
5: E23-E30
[Abstract]
Kittleson, M., Hurwitz, S., Shah, M. R., Nohria, A., Lewis, E., Givertz, M., Fang, J., Jarcho, J., Mudge, G., Stevenson, L. W.
(2003). Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. J Am Coll Cardiol
41: 2029-2035
[Abstract][Full Text]
Shlipak, M. G.
(2003). Pharmacotherapy for Heart Failure in Patients with Renal Insufficiency. ANN INTERN MED
138: 917-924
[Abstract][Full Text]
Kasama, S., Toyama, T., Kumakura, H., Takayama, Y., Ichikawa, S., Suzuki, T., Kurabayashi, M.
(2003). Addition of Valsartan to an Angiotensin-Converting Enzyme Inhibitor Improves Cardiac Sympathetic Nerve Activity and Left Ventricular Function in Patients with Congestive Heart Failure. JNM
44: 884-890
[Abstract][Full Text]
Bolger, A. P, Coats, A. J.S, Gatzoulis, M. A
(2003). Congenital heart disease: the original heart failure syndrome. Eur Heart J
24: 970-976
[Abstract][Full Text]
Khot, U. N., Novaro, G. M., Popovic, Z. B., Mills, R. M., Thomas, J. D., Tuzcu, E. M., Hammer, D., Nissen, S. E., Francis, G. S.
(2003). Nitroprusside in Critically Ill Patients with Left Ventricular Dysfunction and Aortic Stenosis. NEJM
348: 1756-1763
[Abstract][Full Text]
Weber, M.A.
(2003). Angiotensin receptor blockers and the cardiovascular continuum: what future is indicated by recent successes?. Eur Heart J Suppl
5: C1-C4
[Abstract]
Dubey, K, Balani, D K, Pillai, K K
(2003). Potential adverse interaction between aspirin and Lisinopril in hypertensive rats. Hum Exp Toxicol
22: 143-147
[Abstract]
Dart, R. A., Gollub, S., Lazar, J., Nair, C., Schroeder, D., Woolf, S. H.
(2003). Treatment of Systemic Hypertension in Patients With Pulmonary Disease: COPD and Asthma. Chest
123: 222-243
[Abstract][Full Text]
Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Simbre, V. C. II, Shaikh, S. L., Mone, S. M., Gelber, R. D., Colan, S. D.
(2002). Long-Term Enalapril Therapy for Left Ventricular Dysfunction in Doxorubicin-Treated Survivors of Childhood Cancer. JCO
20: 4517-4522
[Abstract][Full Text]
Gottdiener, J. S., McClelland, R. L., Marshall, R., Shemanski, L., Furberg, C. D., Kitzman, D. W., Cushman, M., Polak, J., Gardin, J. M., Gersh, B. J., Aurigemma, G. P., Manolio, T. A.
(2002). Outcome of Congestive Heart Failure in Elderly Persons: Influence of Left Ventricular Systolic Function: The Cardiovascular Health Study. ANN INTERN MED
137: 631-639
[Abstract][Full Text]
Cooke, G.A., Williams, S.G., Marshall, P., Al-Timman, J.K., Shelbourne, J., Wright, D.J., Tan, L.-B.
(2002). A mechanistic investigation of ACE inhibitor dose effects on aerobic exercise capacity in heart failure patients. Eur Heart J
23: 1360-1368
[Abstract][Full Text]
Attia, J, Page, J, Heller, R F, Dobson, A J
(2002). Impact numbers in health policy decisions. J. Epidemiol. Community Health
56: 600-605
[Abstract][Full Text]
El-Solh, A. A., Bozkanat, E., Mador, J., Grant, B. J. B.
(2002). Association Between Plasma Endothelin-1 Levels and Cheyne-Stokes Respiration in Patients With Congestive Heart Failure*. Chest
121: 1928-1934
[Abstract][Full Text]
Zugck, C., Haunstetter, A., Kruger, C., Kell, R., Schellberg, D., Kubler, W., Haass, M.
(2002). Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. J Am Coll Cardiol
39: 1615-1622
[Abstract][Full Text]
McMurray, J., Pfeffer, M. A.
(2002). New Therapeutic Options in Congestive Heart Failure: Part I. Circulation
105: 2099-2106
[Full Text]
Allot, E, de Chillou, C, Sadoul, N
(2002). Ventricular instability and sudden death in patients with heart failure: lessons from clinical trials. Eur Heart J Suppl
4: D31-D42
[Abstract]
Previous
